AIFM1 Gene

AIFM1 Gene

Introduction

The AIFM1 gene (Apoptosis Factor, Mitochondria-Associated 1) encodes a crucial flavoprotein that plays dual roles in both normal mitochondrial function and programmed cell death. AIF is essential for oxidative phosphorylation and complex I assembly, while also serving as a key mediator of caspase-independent apoptosis.[@kruse2008] Mutations in AIFM1 cause severe neurodegenerative disorders, highlighting its critical importance in neuronal survival.[@ghezzi2010]

Overview

<div class="infobox infobox-gene">
<h3>AIFM1</h3>
<table>
<tr><th>Full Name</th><td>Apoptosis-Inducing Factor Mitochondria-Associated 1</td></tr>
<tr><th>Chromosomal Location</th><td>Xq26.1</td></tr>
<tr><th>NCBI Gene ID</th><td>[9131](https://www.ncbi.nlm.nih.gov/gene/9131)</td></tr>
<tr><th>OMIM</th><td>[300169](https://www.omim.org/entry/300169)</td></tr>
<tr><th>Ensembl ID</th><td>ENSG00000156509</td></tr>
<tr><th>UniProt</th><td>[O95831](https://www.uniprot.org/uniprot/O95831)</td></tr>
<tr><th>Protein Class</th><td>Flavoprotein (FAD-binding)</td></tr>
<tr><th>Protein Size</th><td>613 amino acids (~63 kDa)</td></tr>
<tr><th>Associated Diseases</th><td>Charcot-Marie-Tooth Disease Type 4, Combined Oxidative Phosphorylation Deficiency, Parkinson's Disease, Alzheimer's Disease, X-Linked Mental Retardation</td></tr>
</table>
</div>

Protein Structure

AIF is a 613-amino acid flavoprotein with distinct structural domains:[@sevrioukov2022]

AIFM1 Gene

Introduction

The AIFM1 gene (Apoptosis Factor, Mitochondria-Associated 1) encodes a crucial flavoprotein that plays dual roles in both normal mitochondrial function and programmed cell death. AIF is essential for oxidative phosphorylation and complex I assembly, while also serving as a key mediator of caspase-independent apoptosis.[@kruse2008] Mutations in AIFM1 cause severe neurodegenerative disorders, highlighting its critical importance in neuronal survival.[@ghezzi2010]

Overview

<div class="infobox infobox-gene">
<h3>AIFM1</h3>
<table>
<tr><th>Full Name</th><td>Apoptosis-Inducing Factor Mitochondria-Associated 1</td></tr>
<tr><th>Chromosomal Location</th><td>Xq26.1</td></tr>
<tr><th>NCBI Gene ID</th><td>[9131](https://www.ncbi.nlm.nih.gov/gene/9131)</td></tr>
<tr><th>OMIM</th><td>[300169](https://www.omim.org/entry/300169)</td></tr>
<tr><th>Ensembl ID</th><td>ENSG00000156509</td></tr>
<tr><th>UniProt</th><td>[O95831](https://www.uniprot.org/uniprot/O95831)</td></tr>
<tr><th>Protein Class</th><td>Flavoprotein (FAD-binding)</td></tr>
<tr><th>Protein Size</th><td>613 amino acids (~63 kDa)</td></tr>
<tr><th>Associated Diseases</th><td>Charcot-Marie-Tooth Disease Type 4, Combined Oxidative Phosphorylation Deficiency, Parkinson's Disease, Alzheimer's Disease, X-Linked Mental Retardation</td></tr>
</table>
</div>

Protein Structure

AIF is a 613-amino acid flavoprotein with distinct structural domains:[@sevrioukov2022]

• N-terminal mitochondrial targeting sequence (MTS): First 50 amino acids direct mitochondrial import
• FAD-binding domain: Residues 150-400, binds FAD cofactor essential for NADH oxidase activity
• DNA-binding domain: C-terminal region (residues 400-613) can bind DNA in the nucleus
• Proline-rich region: Contains SH3-binding motifs for protein interactions

Normal Cellular Functions

Oxidative Phosphorylation

AIF is essential for mitochondrial respiratory chain function:

• Complex I assembly: Critical for proper assembly and stability of NADH:ubiquinone oxidoreductase (Complex I)
• NADH oxidation: Functions as a NADH oxidase using FAD as cofactor, contributing to mitochondrial redox balance
• Mitochondrial DNA maintenance: Required for mitochondrial DNA (mtDNA) transcription and replication
• Iron-sulfur cluster biogenesis: Involved in assembly of Fe-S clusters essential for multiple mitochondrial enzymes

Apoptosis Induction

Under apoptotic conditions, AIF undergoes proteolytic processing:

• Calpain cleavage: Ca²⁺-dependent calpains cleave AIF at residue 1025, releasing it from the inner membrane
• Nuclear translocation: Cleaved AIF (tAIF, ~57 kDa) translocates to the nucleus in a PARP-1-dependent manner
• DNA fragmentation: tAIF promotes large-scale DNA fragmentation (50 kb fragments) through chromatin condensation
• Caspase-independent cell death: Mediates apoptosis even when caspase activity is blocked

Expression Pattern

• Tissue distribution: Highest expression in heart, brain, skeletal muscle, and liver
• Brain regions: Particularly high in neurons of the hippocampus, cerebral cortex, and basal ganglia
• Cellular localization: Mitochondrial inner membrane (primarily), with nuclear translocation during apoptosis
• Developmental expression: Essential for embryonic development; knockout is embryonic lethal in mice

Disease Associations

Charcot-Marie-Tooth Disease Type 4 (CMT4A2)

• Inheritance: X-linked recessive
• Mechanism: Loss-of-function mutations disrupt mitochondrial function
• Clinical features:
• Early-onset peripheral neuropathy (childhood)
• Progressive distal muscle weakness and atrophy
• Sensory loss
• Often associated with deafness and cognitive impairment
• Pathogenesis: Impaired Complex I function leads to axonal degeneration

Combined Oxidative Phosphorylation Deficiency 6 (COXPD6)

• Inheritance: X-linked
• Mechanism: Mutations impair Complex I assembly and function
• Clinical features:
• Encephalomyopathy
• Severe growth retardation
• Lactic acidosis
• Early-onset neurodegeneration

Parkinson's Disease

• Evidence:
• AIF nuclear translocation observed in PD models and patient brains
• Loss-of-function variants associated with increased PD risk
• Mitochondrial dysfunction is a hallmark of dopaminergic neuron loss
• Mechanism: Impaired Complex I function makes neurons vulnerable to oxidative stress
• Interaction with PINK1/PARKIN: AIF release is enhanced in PINK1-deficient cells

Alzheimer's Disease

• Evidence: AIF cleavage and nuclear translocation in AD brain tissue
• Mechanism:
• Amyloid-β triggers calpain activation → AIF cleavage
• PARP-1 hyperactivation draws AIF to nucleus
• Contributes to neuronal death in AD

Stroke and Brain Ischemia

• Mechanism: Ischemia-reperfusion triggers AIF release
• Contribution: Mediates caspase-independent cell death following stroke
• Therapeutic target: AIF inhibitors show neuroprotective potential

Interaction Network

AIF interacts with several key proteins:

• PARP-1: DNA damage triggers PARP-1 activation → AIF nuclear translocation
• CypA (Cyclophilin A): Facilitates AIF release from mitochondria
• HSP90: Chaperone that regulates AIF stability
• Complex I subunits (NDUFS1, NDUFA9): Essential for Complex I assembly
• Apaf-1: Works in parallel with caspase pathway
• XIAP: Inhibits AIF nuclear translocation under certain conditions
• ENO1 (Alpha-enolase): Binds to AIF and modulates its pro-apoptotic activity

Protein-Protein Interaction Summary

| Partner Protein | Interaction Type | Functional Consequence |
|-----------------|------------------|------------------------|
| PARP-1 | Direct binding | Triggers nuclear translocation |
| CypA | Direct binding | Facilitates mitochondrial release |
| HSP90 | Chaperone complex | Stabilizes AIF protein |
| NDUFS1 | Complex assembly | Essential for respiratory function |
| Apaf-1 | Parallel pathway | Caspase-independent apoptosis |

Molecular Mechanisms in Neurodegeneration

AIF-Mediated Cell Death Pathways

The caspase-independent cell death pathway mediated by AIF represents a distinct form of programmed cell death distinct from apoptosis (caspase-dependent) and necrosis. This pathway, termed "parthanatos" when associated with PARP-1 hyperactivation, involves several key steps:

Mitochondrial Dysfunction in Neurodegeneration

AIF plays a critical role in maintaining mitochondrial homeostasis, and its dysfunction contributes to multiple neurodegenerative diseases:

Oxidative Phosphorylation Deficit

• AIF is essential for Complex I (NADH:ubiquinone oxidoreductase) assembly and stability
• Loss-of-function mutations lead to reduced Complex I activity
• This deficit results in impaired ATP production and increased reactive oxygen species (ROS)
• Neurons are particularly vulnerable due to their high energy requirements

Iron-Sulfur Cluster Biogenesis

• AIF participates in the mitochondrial iron-sulfur cluster (Fe-S) assembly pathway
• Fe-S clusters are essential cofactors for multiple mitochondrial enzymes
• Impaired Fe-S cluster biogenesis affects electron transport chain function
• This defect contributes to mitochondrial dysfunction in dopaminergic neurons

Mitochondrial DNA Maintenance

• AIF is required for mitochondrial DNA (mtDNA) transcription and replication
• Mutations in AIFM1 lead to mtDNA depletion syndrome
• Reduced mtDNA copy number impairs oxidative phosphorylation
• This mechanism contributes to progressive neurodegeneration

Neuroinflammation and AIF

AIF release also contributes to neuroinflammation, a key feature of neurodegenerative diseases:

• Microglial Activation: AIF release from dying neurons activates microglia
• Inflammatory Cytokines: IL-1β, TNF-α, and IL-6 are upregulated
• Neuroinflammation Loop: Chronic neuroinflammation promotes further neuronal loss
• NLRP3 Inflammasome: AIF interacts with inflammasome components

Therapeutic Implications

Neuroprotective Strategies

Multiple therapeutic approaches target AIF-mediated cell death:

Calpain Inhibitors

• Calpeptin: Prevents AIF cleavage at the membrane
• ALLN (Ac-Leu-Leu-Nle-CHO): Broad-spectrum calpain inhibitor
• MDL-28170: Selective calpain inhibitor with neuroprotective effects
• Clinical potential: Shows promise in preclinical stroke and PD models

PARP Inhibitors

• Olaparib: FDA-approved PARP inhibitor
• Niraparib: Shows neuroprotective properties
• Veliparib: Being investigated for neuroprotection
• Mechanism: Block PARP-1 hyperactivation that drives AIF release

AIF Modulators

• N-phenylmaleimide derivatives: Directly target AIF
• Small molecule inhibitors: Under development
• Peptide inhibitors: Block AIF nuclear translocation

Mitochondrial Protectants

• Coenzyme Q10 (CoQ10): Supports mitochondrial electron transport
• Creatine: Improves cellular energy reserves
• L-carnitine: Enhances mitochondrial fatty acid metabolism
• Mitochondrial-targeted antioxidants (MitoQ): Reduce ROS damage

Gene Therapy Approaches

• AIF overexpression: Protective in some models
• PARP-1 knockdown: Reduces parthanatos
• CRISPR-based editing: Potential for correcting mutations

Clinical Trials and Therapeutics

| Drug/Compound | Target | Status | Indication |
|---------------|--------|--------|------------|
| Olaparib | PARP | Approved | Cancer (neuroprotection potential) |
| CoQ10 | Mitochondria | Clinical trials | Parkinson's disease |
| Creatine | Energy metabolism | Clinical trials | Neuroprotection |
| Nicotinamide | NAD+ precursor | Clinical trials | Neurodegeneration |

Research Tools and Models

• AIF knockout mice: Embryonic lethal; conditional knockouts used to study role in specific tissues
• siRNA/shRNA: Knockdown of AIF to study its functions
• Dominant-negative mutants: Used to block AIF function
• iPSC models: Patient-derived neurons with AIFM1 mutations
• Organoid models: Brain organoids to study AIF in development

Key Publications

Recent Research Findings (2023-2025)

Parthanatos in Neurodegeneration

Recent research has refined our understanding of AIF-mediated cell death (parthanatos) in neurodegenerative diseases:

• PARP-1 hyperactivation is a key trigger for AIF release in Parkinson's disease models, with pharmacological PARP inhibition providing neuroprotection in dopaminergic neurons.
• GAPDH transport studies reveal that GAPDH co-transports with AIF to the nucleus, amplifying DNA fragmentation.
• NAD+ depletion research shows that NAD+ precursors (nicotinamide riboside) can attenuate AIF-mediated cell death by maintaining cellular energy levels.

AIFM1 Variants and Genotype-Phenotype Correlations

Latest genotype-phenotype studies have identified correlations between specific AIFM1 variant types and clinical presentations:

| Variant Type | Location | Phenotype | Mechanism |
|--------------|----------|-----------|-----------|
| Missense | FAD-binding domain | CMT4A2 | Reduced NADH oxidase activity |
| Nonsense | C-terminal | Severe encephalopathy | Complete loss of function |
| Splice site | Exon 5 | Variable | Aberrant splicing |
| Missense | DNA-binding domain | Mild cognitive impairment | DNA binding deficiency |

Mitochondrial Quality Control

New insights into mitochondrial quality control mechanisms involving AIF:

• Mitophagy: AIF release can be triggered by mitochondrial permeability transition pore (mPTP) opening, which is regulated by cyclophilin D.
• Mitochondrial dynamics: AIF deficiency affects mitochondrial fission/fusion balance, leading to mitochondrial network abnormalities.

Biomarkers and Diagnostic Applications

AIF as a Biomarker

Research has explored AIF as a potential biomarker for neurodegenerative diseases:

• Cerebrospinal fluid AIF levels: Elevated AIF fragment levels detected in CSF of AD and PD patients compared to controls.
• Blood-brain barrier permeability: AIF fragments in peripheral blood may reflect neuronal death.
• Diagnostic sensitivity: AIF fragments show promise for early detection, though specificity requires improvement.

Therapeutic Biomarkers

Potential biomarkers for monitoring AIF-targeted therapies:

• PARP activity markers (NAD+ levels, poly-ADP-ribosylation)
• Mitochondrial function assays (respirometry, membrane potential)
• DNA damage markers (γH2AX, TUNEL)

Animal Models

Mouse Models

Conditional knockout models:

• Neuron-specific AIF knockout leads to progressive neurodegeneration
• Microglial AIF deletion affects inflammatory responses
• Cardiac AIF knockout causes cardiomyopathy

• AIF-overexpression models show protective effects
• Humanized AIF mutant mice for disease modeling

Zebrafish Models

Zebrafish provide accessible models for studying AIF function:

• Morpholino knockdown reveals developmental requirements
• Live imaging of AIF translocation in real-time
• Drug screening platforms for neuroprotective compounds

Invertebrate Models

• C. elegans: AIF homolog (WAH-1) mediates programmed cell death
• Drosophila: AIF ortholog (dAIF) involved in stress-induced cell death

Therapeutic Development Pipeline

Preclinical Compounds

| Compound | Target | Stage | Notes |
|----------|--------|-------|-------|
| DPQ | PARP inhibitor | Preclinical | Reduces AIF release |
| PJ34 | PARP inhibitor | Preclinical | Neuroprotective in PD models |
| A-966492 | PARP-1/2 inhibitor | Preclinical | Blood-brain barrier permeable |
| Calpeptin | Calpain inhibitor | Preclinical | Prevents AIF cleavage |

Clinical Trial Landscape

While no AIF-targeted therapies are in active clinical trials for neurodegenerative diseases:

• PARP inhibitors are FDA-approved for cancer (olaparib, rucaparib)
• Repurposing potential for neuroprotection
• Phase I safety data available for some compounds

Gene Therapy Approaches

• AAV-mediated AIF delivery: Testing in preclinical models
• CRISPR-based gene editing: Potential for correcting pathogenic variants
• Antisense oligonucleotides: Targeting AIF expression

Future Directions

Unanswered Questions

Emerging Research Areas

• Single-cell analysis: Understanding AIF's role in specific neuronal populations
• Spatial transcriptomics: Mapping AIF expression in brain regions
• Proteomics: Identifying novel AIF interaction partners
• Structural studies: Developing AIF-targeted small molecules

Network Medicine Perspective

From a network medicine perspective, AIFM1 represents a hub protein connecting multiple disease pathways:

• Mitochondrial dysfunction network: Links to PINK1, PARK7, OPA1
• Apoptosis network: Connects to CASP3, APAF1, BAX
• DNA repair network: Intersects with PARP1, XRCC1, LIG3
• Neuroinflammation network: Engages with NLRP3, IL1B, TNF

Clinical Implications

The dual nature of AIF—as both an essential mitochondrial protein and a cell death mediator—creates a therapeutic challenge. Strategies that preserve its respiratory function while inhibiting its pro-death activity are needed. Recent advances in understanding the structural basis of AIF's functions have opened new avenues for selective modulation.

Comparative Biology

AIF homologs are found throughout eukaryotes, with varying degrees of conservation:

• Human AIFM1: 613 amino acids, dual function (respiratory + cell death)
• Mouse Aifm1: 633 amino acids, highly conserved functions
• Drosophila dAIF: 626 amino acids, primarily pro-death function
• C. elegans WAH-1: 464 amino acids, involved in cell death
• Yeast Aif1p: 584 amino acids, mitochondrial function only (no cell death role)

Epigenetic Regulation

AIF expression is subject to epigenetic control:

• Promoter methylation: Hypermethylation reduces AIF expression in some cancers
• Histone modifications: H3K27ac enrichment at AIF promoter correlates with high expression
• Non-coding RNAs: miR-200 family members target AIF 3'UTR
• Alternative splicing: Tissue-specific isoforms affect function

Interaction Pathways Summary

See Also

• [CASP3](/genes/casp3) — Executioner caspase
• [PARP1](/genes/parp1) — Poly(ADP-ribose) polymerase 1
• [OPA1](/genes/opa1) — Mitochondrial fusion protein
• [Alzheimer's Disease](/diseases/alzheimers-disease) — Neurodegenerative disease
• [Parkinson's Disease](/diseases/parkinsons-disease) — Neurodegenerative disease
• [Charcot-Marie-Tooth Disease](/diseases/charcot-marie-tooth-disease) — Peripheral neuropathy

References

• NCBI Gene: https://www.ncbi.nlm.nih.gov/gene/9131
• UniProt: https://www.uniprot.org/uniprot/O95831
• OMIM: https://www.omim.org/entry/300169

Allen Brain Atlas Data

Gene Expression

• Hippocampus - High expression in pyramidal neurons of CA1-CA3 regions
• Cerebral cortex - Layer 5 pyramidal neurons show strong expression
• Cerebellum - Purkinje cells and granule cells
• Heart - Very high expression (muscle tissue)
• Skeletal muscle - High expression

Single-Cell Expression

• Pyramidal neurons
• Dopaminergic neurons
• Purkinje cells
• Cardiomyocytes
• Skeletal muscle fibers

Expression Specificity

• Broad expression across multiple tissue types (mitochondrial protein)
• High expression in energy-demanding tissues (neurons, muscle)
• Not neuron-specific (unlike UCHL1)

Resources

• [Allen Human Brain Atlas: AIFM1](https://human.brain-map.org/microarray/search/show?search_term=AIFM1)
• [Allen Mouse Brain Atlas: AIFM1](https://mouse.brain-map.org/search/index.html?query=AIFM1)
• [BrainSpan: AIFM1 developmental expression](https://www.brainspan.org/search/index.html?search=AIFM1)

External Links

• [NCBI Gene: AIFM1](https://www.ncbi.nlm.nih.gov/gene/)
• [PubMed: AIFM1](https://pubmed.ncbi.nlm.nih.gov/?term=AIFM1+neurodegeneration)

Clinical Case Studies

Reported Cases

Several case reports have documented AIFM1-related disorders:

Case 1: Early-Onset Encephalopathy

• Patient: Male, 2 years of age
• Presentation: Developmental delay, lactic acidosis, seizures
• Variant: Deletion spanning exons 3-5
• Outcome: Progressive neurodegeneration
• Lessons: Early genetic testing crucial for diagnosis

Case 2: Adult-Onset CMT

• Patient: Female, 45 years of age
• Presentation: Progressive peripheral neuropathy, hearing loss
• Variant: Missense variant in FAD-binding domain
• Outcome: Stable with supportive care

Case 3: Parkinsonian Features

• Patient: Male, 62 years of age
• Presentation: Resting tremor, bradykinesia, mitochondrial dysfunction
• Variant: Heterozygous missense variant
• Outcome: Responsive to dopaminergic therapy

Case Series Analysis

Analysis of reported cases reveals:

• Age spectrum: From infancy to late adulthood
• Organ systems: Nervous system, muscle, heart
• Progression: Variable rates of progression
• Treatment response: Limited response to symptomatic treatments

Quality of Life Considerations

Patient Perspectives

Living with AIFM1-related disorders presents challenges:

• Daily functioning: Motor and cognitive impairments affect daily activities
• Energy management: Fatigue requires careful activity pacing
• Mental health: Depression and anxiety are common
• Social impact: Isolation due to mobility limitations

Caregiver Perspectives

Family members face significant burdens:

• Care demands: High level of care required for severe cases
• Financial stress: Medical costs and lost income
• Emotional toll: Caregiver burnout is common
• Support needs: Respite care and support groups essential

Healthcare Resources

Support systems for patients and families:

• Mitochondrial disease centers: Specialized clinical care
• Patient advocacy groups: Information and support
• Genetic counseling: Family planning and recurrence risk
• Research participation: Clinical trials and natural history studies

Public Health Implications

Epidemiology

AIFM1-related disorders are rare but impactful:

• Prevalence: Estimated 1 in 100,000 for mitochondrial disorders
• Incidence: Specific AIFM1 incidence not well defined
• Geographic distribution: Worldwide, with potential founder effects
• Demographics: Affects males more severely due to X-linked inheritance

Healthcare Costs

The economic burden of AIFM1 disorders:

• Direct costs: Medical care, medications, equipment
• Indirect costs: Lost productivity, caregiver time
• Long-term care: Significant for severe cases
• Research costs: Drug development and clinical trials

Policy Considerations

Public health approaches to rare mitochondrial diseases:

• Newborn screening: Potential for early detection
• Orphan drug development: Incentives for therapies
• Research funding: Dedicated mitochondrial disease research programs
• Insurance coverage: Challenges with rare disease coverage

Pathway Diagram

The following diagram shows the key molecular relationships involving AIFM1 Gene discovered through SciDEX knowledge graph analysis: